Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia

Chadi Nabhan, Kari G. Chaffee, Susan L Slager, Natalie Galanina, Sara J. Achenbach, Susan M. Schwager, Neil Elliot Kay, Tait D. Shanafelt

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The impact of race on outcomes of patients with chronic lymphocytic leukemia (CLL), the most common leukemia in the west, is not well studied. We aimed to understand racial variations in clinical and disease characteristics, treatment patterns, and outcomes in patients with CLL. We utilized the Mayo Clinic CLL database to perform an analysis of these characteristics and natural history of non-white (NW) compared to white (W) CLL patients. Differences by race in median overall survival (OS) and time-to-first-treatment (TTFT) were investigated. Of the 4215 CLL patients, 4114 (97.6%) were W and 101 (2.4%) were NW. NW patients were younger (median age at diagnosis 59.4 vs. 63.4; P = 0.003) and more likely to have an elevated LDH (28.0% vs. 16.2%; P = 0.02). No differences in prognostic parameters were noted. No major differences were observed in treatment selection. OS and TTFT were similar between both groups. In the largest analysis of NW-CLL patients in North America, and contrary to historical retrospective reports, W and NW patients appear to have comparable outcomes when treated similarly. These findings suggest previously noted outcome differences may be due to disparities in access to care and management rather than differences in disease biology. Am. J. Hematol. 91:677–680, 2016.

Original languageEnglish (US)
Pages (from-to)677-680
Number of pages4
JournalAmerican Journal of Hematology
Volume91
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Survival
North America
Natural History
Leukemia
Therapeutics
Databases

ASJC Scopus subject areas

  • Hematology

Cite this

Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. / Nabhan, Chadi; Chaffee, Kari G.; Slager, Susan L; Galanina, Natalie; Achenbach, Sara J.; Schwager, Susan M.; Kay, Neil Elliot; Shanafelt, Tait D.

In: American Journal of Hematology, Vol. 91, No. 7, 01.07.2016, p. 677-680.

Research output: Contribution to journalArticle

Nabhan, Chadi ; Chaffee, Kari G. ; Slager, Susan L ; Galanina, Natalie ; Achenbach, Sara J. ; Schwager, Susan M. ; Kay, Neil Elliot ; Shanafelt, Tait D. / Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. In: American Journal of Hematology. 2016 ; Vol. 91, No. 7. pp. 677-680.
@article{a0195be18aa947b88d163aae693d9329,
title = "Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia",
abstract = "The impact of race on outcomes of patients with chronic lymphocytic leukemia (CLL), the most common leukemia in the west, is not well studied. We aimed to understand racial variations in clinical and disease characteristics, treatment patterns, and outcomes in patients with CLL. We utilized the Mayo Clinic CLL database to perform an analysis of these characteristics and natural history of non-white (NW) compared to white (W) CLL patients. Differences by race in median overall survival (OS) and time-to-first-treatment (TTFT) were investigated. Of the 4215 CLL patients, 4114 (97.6{\%}) were W and 101 (2.4{\%}) were NW. NW patients were younger (median age at diagnosis 59.4 vs. 63.4; P = 0.003) and more likely to have an elevated LDH (28.0{\%} vs. 16.2{\%}; P = 0.02). No differences in prognostic parameters were noted. No major differences were observed in treatment selection. OS and TTFT were similar between both groups. In the largest analysis of NW-CLL patients in North America, and contrary to historical retrospective reports, W and NW patients appear to have comparable outcomes when treated similarly. These findings suggest previously noted outcome differences may be due to disparities in access to care and management rather than differences in disease biology. Am. J. Hematol. 91:677–680, 2016.",
author = "Chadi Nabhan and Chaffee, {Kari G.} and Slager, {Susan L} and Natalie Galanina and Achenbach, {Sara J.} and Schwager, {Susan M.} and Kay, {Neil Elliot} and Shanafelt, {Tait D.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1002/ajh.24374",
language = "English (US)",
volume = "91",
pages = "677--680",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia

AU - Nabhan, Chadi

AU - Chaffee, Kari G.

AU - Slager, Susan L

AU - Galanina, Natalie

AU - Achenbach, Sara J.

AU - Schwager, Susan M.

AU - Kay, Neil Elliot

AU - Shanafelt, Tait D.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - The impact of race on outcomes of patients with chronic lymphocytic leukemia (CLL), the most common leukemia in the west, is not well studied. We aimed to understand racial variations in clinical and disease characteristics, treatment patterns, and outcomes in patients with CLL. We utilized the Mayo Clinic CLL database to perform an analysis of these characteristics and natural history of non-white (NW) compared to white (W) CLL patients. Differences by race in median overall survival (OS) and time-to-first-treatment (TTFT) were investigated. Of the 4215 CLL patients, 4114 (97.6%) were W and 101 (2.4%) were NW. NW patients were younger (median age at diagnosis 59.4 vs. 63.4; P = 0.003) and more likely to have an elevated LDH (28.0% vs. 16.2%; P = 0.02). No differences in prognostic parameters were noted. No major differences were observed in treatment selection. OS and TTFT were similar between both groups. In the largest analysis of NW-CLL patients in North America, and contrary to historical retrospective reports, W and NW patients appear to have comparable outcomes when treated similarly. These findings suggest previously noted outcome differences may be due to disparities in access to care and management rather than differences in disease biology. Am. J. Hematol. 91:677–680, 2016.

AB - The impact of race on outcomes of patients with chronic lymphocytic leukemia (CLL), the most common leukemia in the west, is not well studied. We aimed to understand racial variations in clinical and disease characteristics, treatment patterns, and outcomes in patients with CLL. We utilized the Mayo Clinic CLL database to perform an analysis of these characteristics and natural history of non-white (NW) compared to white (W) CLL patients. Differences by race in median overall survival (OS) and time-to-first-treatment (TTFT) were investigated. Of the 4215 CLL patients, 4114 (97.6%) were W and 101 (2.4%) were NW. NW patients were younger (median age at diagnosis 59.4 vs. 63.4; P = 0.003) and more likely to have an elevated LDH (28.0% vs. 16.2%; P = 0.02). No differences in prognostic parameters were noted. No major differences were observed in treatment selection. OS and TTFT were similar between both groups. In the largest analysis of NW-CLL patients in North America, and contrary to historical retrospective reports, W and NW patients appear to have comparable outcomes when treated similarly. These findings suggest previously noted outcome differences may be due to disparities in access to care and management rather than differences in disease biology. Am. J. Hematol. 91:677–680, 2016.

UR - http://www.scopus.com/inward/record.url?scp=84973912581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973912581&partnerID=8YFLogxK

U2 - 10.1002/ajh.24374

DO - 10.1002/ajh.24374

M3 - Article

C2 - 27013143

AN - SCOPUS:84973912581

VL - 91

SP - 677

EP - 680

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -